STOCK TITAN

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

NextCure Inc (Nasdaq: NXTC) announced two presentations at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in Houston, TX from November 6-10, 2024. The company will present:

1. Pre-clinical data on LNCB74, a B7-H4 antibody-drug conjugate, in a poster session on November 8.

2. Biomarker data from the NC410 combination study with pembrolizumab in ICI-naïve MSS/MSI-L colorectal cancer, in a poster session on November 9.

These presentations showcase NextCure's ongoing research in novel cancer therapies, particularly in antibody-drug conjugates and combination immunotherapies.

NextCure Inc (Nasdaq: NXTC) ha annunciato due presentazioni alla prossima riunione annuale della Society for Immunotherapy of Cancer (SITC) che si terrà a Houston, TX, dal 6 al 10 novembre 2024. L'azienda presenterà:

1. Dati preclinici su LNCB74, un coniugato di anticorpi e farmaci B7-H4, in una sessione di poster l'8 novembre.

2. Dati sui biomarcatori dallo studio combinato NC410 con pembrolizumab nel cancro colorettale MSS/MSI-L naïve agli ICI, in una sessione di poster il 9 novembre.

Queste presentazioni evidenziano la ricerca continua di NextCure nelle nuove terapie oncologiche, in particolare nei coniugati di anticorpi e nelle immunoterapie combinate.

NextCure Inc (Nasdaq: NXTC) anunció dos presentaciones en la próxima reunión anual de la Society for Immunotherapy of Cancer (SITC) en Houston, TX, del 6 al 10 de noviembre de 2024. La empresa presentará:

1. Datos preclínicos sobre LNCB74, un conjugado de anticuerpo-fármaco B7-H4, en una sesión de póster el 8 de noviembre.

2. Datos de biomarcadores del estudio de combinación NC410 con pembrolizumab en cáncer colorrectal MSS/MSI-L naive a ICI, en una sesión de póster el 9 de noviembre.

Estas presentaciones muestran la investigación continua de NextCure en nuevas terapias contra el cáncer, especialmente en conjunciones de anticuerpos e inmunoterapias combinadas.

NextCure Inc (Nasdaq: NXTC)는 2024년 11월 6일부터 10일까지 텍사스주 휴스턴에서 열리는 암 면역요법 학회(SITC) 연례 회의에서 두 가지 발표를 할 것이라고 발표했습니다. 회사는 다음과 같이 발표할 예정입니다:

1. 11월 8일 포스터 세션에서 B7-H4 항체-약물 접합체인 LNCB74에 대한 전임상 데이터를 발표합니다.

2. 11월 9일 포스터 세션에서 ICI-Naïve MSS/MSI-L 대장암에서 pembrolizumab과의 NC410 조합 연구의 바이오마커 데이터를 발표합니다.

이 발표는 새로운 암 치료법, 특히 항체-약물 접합체 및 조합 면역 요법에 대한 NextCure의 지속적인 연구를 보여줍니다.

NextCure Inc (Nasdaq: NXTC) a annoncé deux présentations lors de la prochaine réunion annuelle de la Society for Immunotherapy of Cancer (SITC) à Houston, TX, du 6 au 10 novembre 2024. L'entreprise présentera :

1. Des données précliniques sur LNCB74, un conjugué anticorps-médicament B7-H4, lors d'une session de posters le 8 novembre.

2. Des données sur des biomarqueurs de l'étude de combinaison NC410 avec pembrolizumab dans le cancer colorectal MSS/MSI-L naïf aux ICI, lors d'une session de posters le 9 novembre.

Ces présentations mettent en valeur la recherche continue de NextCure dans de nouvelles thérapies contre le cancer, en particulier dans les conjugués anticorps-médicaments et les immunothérapies combinées.

NextCure Inc (Nasdaq: NXTC) hat zwei Präsentationen auf dem bevorstehenden Jahrestreffen der Society for Immunotherapy of Cancer (SITC) in Houston, TX, vom 6. bis 10. November 2024 angekündigt. Das Unternehmen wird präsentieren:

1. Präklinische Daten zu LNCB74, einem B7-H4 Antikörper-Wirkstoff-Konjugat, in einer Postersession am 8. November.

2. Biomarker-Daten aus der NC410 Kombinationsstudie mit Pembrolizumab bei ICI-naiven MSS/MSI-L Kolorektalkrebs, in einer Postersitzung am 9. November.

Diese Präsentationen zeigen NextCures fortlaufende Forschung in neuen Krebstherapien, insbesondere bei Antikörper-Wirkstoff-Konjugaten und Kombinationstherapien.

Positive
  • Presenting pre-clinical data on LNCB74, a potential new cancer therapy
  • Sharing biomarker data from NC410 combination study, indicating progress in clinical research
  • Participation in a major cancer research conference, demonstrating industry engagement
Negative
  • None.

BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Houston, TX from November 6-10, 2024. NextCure will share pre-clinical data from LNCB74 (B7-H4 ADC) and biomarker data from NC410 combination study with pembrolizumab in ICI-naïve MSS/MSI-L CRC during poster sessions.

Poster Presentation Details:

Title: LNCB74 is a B7-H4 antibody-drug conjugate with a β-glucuronide linker-MMAE payload system to enhance therapeutic index in B7-H4 expressing cancers
Lead Author: Shannon M. Kahan
Abstract Number: 1051
Session Date & Time: Friday, November 8, 2024, 5:30 – 7:00 PM

Title: NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naive MSS/MSI-L colorectal cancer (CRC)
Lead Author: Alina Barbu
Abstract Number: 632
Session Date & Time: Saturday, November 9, 2024, 7:10 – 8:30 PM

About NextCure, Inc.

NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. http://www.nextcure.com

Cautionary Statement Regarding Forward-Looking Statements

Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and NextCure’s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com


FAQ

What presentations will NextCure (NXTC) give at the SITC 2024 annual meeting?

NextCure will give two poster presentations at SITC 2024: one on LNCB74, a B7-H4 antibody-drug conjugate, and another on NC410 in combination with pembrolizumab for colorectal cancer treatment.

When and where will NextCure (NXTC) present at the SITC 2024 annual meeting?

NextCure will present at the SITC annual meeting in Houston, TX from November 6-10, 2024. The LNCB74 presentation is on November 8, and the NC410 combination study presentation is on November 9.

What is the focus of NextCure's (NXTC) LNCB74 presentation at SITC 2024?

The LNCB74 presentation focuses on a B7-H4 antibody-drug conjugate with a β-glucuronide linker-MMAE payload system designed to enhance therapeutic index in B7-H4 expressing cancers.

What is the subject of NextCure's (NXTC) NC410 combination study presentation at SITC 2024?

The NC410 presentation discusses how the combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naive MSS/MSI-L colorectal cancer.

NextCure, Inc.

NASDAQ:NXTC

NXTC Rankings

NXTC Latest News

NXTC Stock Data

37.21M
27.98M
8.85%
57.45%
0.26%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BELTSVILLE